Trial Profile

Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tirzepatide (Primary)
Indications Type 2 diabetes mellitus
Focus Pharmacokinetics
Sponsors Eli Lilly and Company (India) Pvt. Ltd

Most Recent Events

29 Mar 2021 Results published in the Clinical Pharmacokinetics
25 Sep 2020 Results assessing impact of Renal impairment on the clinical pharmacokinetics of tirzepatide, presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
16 Jun 2020 Results evaluating the pharmacokinetics and tolerability of Tirzepatide in subjects with renal impairment (with or without T2DM) vs. healthy subjects with normal renal function, presented at the 80th Annual Scientific Sessions of the American Diabetes Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com